Premium
Unexpected hepatotoxicity after priming and treatment with molgramostim (rhGM‐CSF) in acute myeloid leukemia during induction chemotherapy
Author(s) -
Hansen Per Boye,
Johnsen Hans E.,
Lund Jens Otto,
Hansen Mogens Sandbjerg,
Hansen Niels Ebbe
Publication year - 1995
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830480110
Subject(s) - medicine , chemotherapy , myeloid leukemia , gastroenterology , induction chemotherapy , adverse effect , granulocyte macrophage colony stimulating factor , myeloid , oncology , immunology , cytokine
The effect of supplementing induction chemotherapy with recombinant human granulocyte‐macrophage colony‐stimulating factor (rhGM‐CSF) was studied in a randomized trial of 18 patients with acute myeloid leukemia (AML). Ten patients received rhGM‐CSF, starting on day one to three before chemotherapy and continued for a maximum of 21 days after the start of induction treatment. Unexpected adverse effects of rhGM‐CSF and chemotherapy combination included a transient decline in plasma coagulation factors II, VII, and X (5 of 5 patients) and an increased transcapillary escape rate of albumin (in 3 of 3 patients tested). The decline in coagulation factors was prevented in subsequent patients by prophylactic treatment with vitamin K. Although the small number of patients studied may not allow a definite conclusion, caution with regard to liver function should be shown in combining rhGM‐CSF with intensive chemotherapy. ©1995 Wiley‐Liss, Inc.